EGFR and melanoma: Additionally, loss of Bim or its expression in melanoma, colorectal cancer, intrahepatic cholangiocarcinoma, and EGFR-positive NSCLC is associated with worse prognoses (Dai et al., 2008; Sinicrope et al., 2008; Ng et al., 2012; Lee et al., 2015; Zhang et al., 2018).